G MEDICAL INNOVATIONS

A NEW ERA IN HEALTHCARE

Oct 2017

OUTLINE

THIS IS A CONFIDENTIAL DOCUMENT

This presentation is not a prospectus nor an offer for securities in any jurisdiction nor a securities recommendation. The information in this presentation is an overview and does not contain all information necessary for investment decisions. In making investment decisions in connection with any acquisition of securities, investors should rely on their own examination of the assets and consult their own legal, business and/or financial advisers.

The information contained in this presentation has been prepared in good faith by G Medical Innovations Ltd (G Medical), however no representation or warranty expressed or implied is made as to the accuracy, correctness, completeness or adequacy of any statements, estimates, opinions or other information contained in this presentation.

To the maximum extent permitted by law, G Medical, its directors, officers, employees and agents disclaim liability for any loss or damage which may be suffered by any person through the use or reliance on anything contained in or omitted in this presentation.

Certain information in this presentation refers to the intentions of G Medical, but these are not intended to be forecasts, forward looking statements or statements about future matters for the purposes of the corporations act or any other applicable law. The occurrence of events in the future are subject to risks, uncertainties and other factors that may cause G Medical's actual results, performance or achievements to differ from those referred to in this presentation.

Accordingly, G Medical, its directors, officers, employees and agents do not give any assurance or guarantee that the occurrence of the events referred to in the presentation will actually occur as contemplated.

1

. . . .

G MEDICAL
OVERVIEW

G Medical Innovations is at the forefront of the digital health revolution in developing the next generation of mobile technologies that will empower consumers and providers to better monitor, manage, and improve clinical and personal health outcomes.

- Founded in 2014
- Public company – traded in the ASX (GMV)
- Global Presence

USA

CYPRUS
ISRAEL

CHINA
HONG KONG

AUSTRALIA

THE COMPANY'S VISION

G-Medical Innovations is ushering in a new era of healthcare and wellness by utilizing its patented wireless technologies, and proprietary information technology and service platforms, to empower a new generation of consumers, patients and providers to improve quality of life by:

ENABLING EARLY DETECTION

+

IMPROVING HEALTHCARE OUTCOMES

+

REDUCING COSTS

+

EXPANDING ACCESS TO CLINICALLY RELEVANT INFORMATION

MILESTONES

US$5M
Investment received from G Medical JV partner – Chinese fund Guangzhou Sino-Israel Bio Industry

CE certification
received for Prizma Smartphone Case

ASX listing raising
A$12M

US$67.5M
Binding MOU signed with Shadong Boletong Information S&T Co.

1H FY18
CFDA expected approval (case)

2H FY17
CE & FDA expected approval

FDA approval
received for Prizma Smartphone Case

1H FY18
CFDA expected approval

| MAY 17 | JUNE 17 | JULY 17 | AUG 17 | SEP 17 | JAN 18 |

Source: Management

2

MANAGEMENT & BOARD

MANAGEMENT PROFILE

The founders and executive leaders at G Medical Innovations offer a wealth of expertise in developing best in class products, services, and commercial businesses to address the global demand for mobile and digital health. They offer a legacy of engineering and product development excellence in addressing the unmet needs and demands across healthcare. The leadership team brings unparalleled experience in combining medical, electronics, embedded software, and body sensors to create sustainable and profitable businesses.

The leadership team has the depth of expertise individually and collectively in contributing to several successful businesses from $100M to $15B, including mergers, acquisitions, and IPO.

An adept and experienced team in healthcare services that managed in excess of 50,000 new patients per month with multiple clinical call centers, including distribution, offshore monitoring, finance, reimbursement, payer contracting, among others. The end result is consistent execution, increased margins and profitability, and a high net return for employees, shareholders, and investors.

MANAGEMENT TEAM

Established track record in commercialising medical devices

Dr. Yacov Geva

Chief Executive Officer
Executive Director

A well-known pioneer in the industry of Medical Devices and remote monitoring services, and co-founder of LifeWatch AG (former Card Guard AG and Card Guard Scientific Survival Ltd.). Successfully led Liefwatch to an IPO.

Dr. Geva holds a B.Sc in Mechanical and Nuclear Engineering, a Ph.D. (with honors) in Business Administration from the International School of Management, Paris and an honorary doctorate from Oxford Brooks University.

Dr. Geva is also a senior member of the royal society of medicine in the UK (RSM).

Mr. Kobi Ben-Efraim

Chief Financial Officer

An experienced and senior CFO of global companies with more than 20 years' experience in the finance and accounting domain. He has served in Israeli high tech companies including DSPC Group (a NASDAQ-traded company) and El-Op.

Mr. Ben-Efraim holds a B.A. in Economics and Accounting from Tel Aviv University, and is a Certified Public Accountant (IL).

Mr. Mark Bogart

EVP Sales and Business
Development IDTF/Hospitals

Mr. Bogart has a track record of over 20 years as an executive in the medical device and healthcare services. He is a subject matter expert in mHealth, wireless telemedicine and remote monitoring, and brings also substantial experience in strategic business development and managing and directing sales force teams.

Mr. Rafi Heumann

Chief Operating Officer

Mr. Heumann has over 20 years of experience in Hi-tech, mHealth, operations and services industries. He brings with him advanced skills in strategic planning, international negotiations and business development, and directing complex projects. Mr. Heumann has business management education from Bar-Ilan University, Israel.

Mr. Louis Antoniou

EVP Business Dev.
mHealth Executive Director

Mr. Antoniou is considered an industry pioneer with history of innovative program evolution and cutting-edge product launches. He has diverse industry sales channel experience including telecommunications, electronics, automotive, distribution and information technology.

Mr. Antoniou has a bachelor's degree in economics from the University of Bridgeport.

Mr. Nir Geva

Chief Technology Officer, Vice President
of Research and Development

Mr. Geva has over 17 years of experience in the Hi-Tech and Medical Device industry, and is former CTO and strategic projects manager at Lifewatch Technologies. He brings with him a broad knowledge on products definition and development, project management and manufacturing of medical devices. He has also been involved in projects in the fields of Mobile Apps and IoT and wrote over 15 patents related to Medical Devices, Remote Patients Monitoring and IoT. Mr. Geva holds a BSc. in Mechanical Engineering from the Technion in Haifa and an Executive MBA from Kellogg school of management (Northwestern University in Chicago).

BOARD OF DIRECTORS

Diverse international Board, with expertise in growth companies

Dr. Yacov Geva

Chief Executive Officer
Executive Director

Mr. Louis Antoniou

EVP Business Dev.
mHealth Executive Director

Dr. Kenneth R. Melani

Non Executive Chairman

Dr. Melani has over 30 years' experience in the healthcare industry as a provider, supplier and insurer. He has started seven successful for-profit health services businesses and has served in various critical business roles including CEO, Chief Medical Office, and Strategy and Business Development.

During his tenure as President and CEO of Highmark Inc. in 2003 to 2012, he grew the company into one of the largest and most diversified healthcare companies in the United States, serving over 32 million individuals. He has been an investor in numerous pre- IPO investments since 1985 and was instrumental for several successful IPOs in Switzerland.

Mr. Sam Skontos

Non Executive Director

Sam Skontos has a career spanning 28 years in sales and marketing in Australia, New Zealand and Asia. He holds a Bachelor of Engineering (Electrical) from the University of NSW and has extensive experience in the technology and communications sectors.

Dr. Shuki Gleitman

Non Executive Director

Dr. Gleitman is the Chairman of the Guangzhuo Israel Biotech Fund, Chairman of the Board of Directors of Capital Point Group, a Board member and Chairman of the audit and financial committees of Elbit Systems (NASDAQ, TLV traded), Chairman of the YoYa Group, Senior Advisor to the World Bank (national policy for innovation) and Senior Strategy Advisor to Serbia Innovation Fund.

Prior to this, Dr. Gleitman was the Chief Scientist and Director General of Israel's Ministry of Industry and Trade, where he managed all of the Israeli Government technological programs.

Mr. Urs Wettstein

Non Executive Director

Mr Wettstein has an accounting, auditing and taxation background in Switzerland, having founded his own accounting firm and also worked with Coopers and Lybrand AG in Zurich. He has been an advisor and investor in numerous pre- IPO investments since 1985 and was instrumental for several successful IPOs in Switzerland.

Dr. Brendan de Kauwe

Non Executive Director

Dr. de Kauwe is a Director of Otsana Capital, a corporate advisory firm in Western Australia experienced in corporate restructuring and recapitalisations, mergers and acquisitions, IPO/RTO transactions and capital markets.

He is currently Chairman of eSense-Lab Ltd (ASX:ESE), and Director of Race Oncology Ltd (ASX:RAC) and Ookami Ltd (ASX:OOK).

Mr. Ashley Krongold

Non Executive Director

Mr Krongold is the CEO of the Krongold Group, a third-generation, family-run group of companies based in Melbourne with businesses spanning various industries. Prior to Krongold Group, Ashley spent 15 years in the IB and Accounting industries. He was a founding member of Investec Bank Australia, worked at William Buck Chartered Accountants, ANZ Corporate Finance (London) and ANZ Private Bank (Australia) He is a Non-executive Director of Weebit Non Ltd (ASX:WBT) and Dotz Nano Limited (ASX:DTZ). Ashley is also a founding General Partner of global equity crowd-funding platform, OurCrowd.

3

. . . .

THE REMOTE
MONITORING MARKET

THE GLOBAL HEALTHCARE CHALLENGE

mHEALTH IS THE SOLUTION FOR RISING COMPLEXITY AND COST

Healthcare spending as % of GDP is increasing:

- US: 17% and rising.
- OECD: 9% and rising.
- EU: 10% and rising.

As patients become more demanding and providers' constraints more challenging, cost-effective health solutions and access become a top priority.

mHealth provides answers for major healthcare challenges:

- Improved productivity and efficiency.
- Better utilisation of centralised assets and scarce talent resources.

Source: World Bank, OECD, European Commission

Patients - Aging, more self-guided, more obese, suffering from increasingly complex and chronic diseases

Providers - Rising treatment costs, shortage of talent, growing capacity and budget constraints

Payers - Increasing pressure to provide quality of care and contain costs

Government - Increasing access to care, pressure to provide cost-effective, high-quality outcomes

HOSPITAL RE-ADMISSIONS IN THE USA

ANNUAL READMISSION COSTS TOTAL ABOUT $53 BILLION

- The federal Center for Medicare & Medicaid Services (CMS) determines readmissions as patients returning to the hospital within 30 days of discharge.

- In 2014, Medicare's Hospital Readmissions Reduction Program increased penalties and expanded the criteria, resulting in a loss of up to 3% of Medicare reimbursements, estimated to total $428 million in FY2014.

- Approximately 2 million Medicare patients are readmitted each year, consisting about 50% of all readmissions, costing Medicare $26 billion. Officials estimate $17 billion in costs from potentially avoidable readmissions.

PAYER	NUMBER OF READMITTED STAYS
Medicare	2,294,895
Medicaid	767,902
Private Insurance	689,467
Uninsured	166,367

Age Group	Number of Stays	Average Cost per Stay ($)	Number of Readmitted Stays	Percent Readmitted	Average Cost per Readmitted Stay ($)	% Change in Costs
1-17	1,354,434	9,566	140,141	10%	14,734	54%
18-44	8,234,233	7,621	799,516	10%	10,300	35%
45-64	8,101,243	12,912	1,260,752	16%	13,736	6%
65+	11,143,495	12,682	1,840,635	17%	13,547	7%
Total	**28,833,405**	**11,160**	**4,041,044**	**14%**	**13,003**	**17%**

Source: US Department of Health and Human Services, Center for Medicare & Medicaid Services, Juniper Research, Brookings Institution

THE OPPORTUNITY – REMOTE MONITORING

MAJOR CAUSES OF READMISSIONS & G MEDICAL'S SOLUTIONS

TYPE OF DIAGNOSIS			
CARDIAC	**PULMONARY**	**OTHER**	**GEN 2/3 INDICATIONS**
• Congestive heart failure • Cardiac dysrhythmias • Acute myocardial infarction • Acute cerebrovascular dis-ease • Coronary atherosclerosis and other heart disease • Nonspecific chest pain	• Chronic obstructive pulmonary disease and bronchiectasis • Pneumonia (except that caused by TB or STD)	• Urinary tract infections • Maintenance chemotherapy; radio-therapy • Other complications of pregnancy • Complications of surgical procedures or medical care • Alcohol-related disorders • Skin and subcutaneous tissue • infections	• Diabetes • Obesity • Pregnancy • Kidney Disease • Nephrolithiasis • CVD • Anemia • Cancer • Athletes
G MEDICAL'S SOLUTION (VSMS & COVER)			
• ECG • Heart Rate	• SPO2 • Respiration Rate	• Blood Pressure • Temperature	• Blood Glucose • Uric Acid • Cholesterol • Haemoglobin

3

G MEDICAL
PRODUCT SUITE

prizma G2

PRIZMA SENSORS

Simply place the Prizma sensors on your smartphone and start taking tests.

PRIZMA APP

The Prizma app is always with you on your smartphone. Download it from the Apple App Store™ or Google Play™.

MEDICAL PORTAL

View your test results and medical history and easily share.

COMPLETE SOLUTION

FDA APPROVED

APPROVED CE

PRIZMA

PRIZMA TESTS SUITE

VITAL SIGNS AND BIOMETRIC MONITORING

Current
- ECG measurement
- Respiration
- SpO2 – Oxygen Saturation Level
- Heart rate
- Thermometer – body temp
- Stress analysis

In the pipeline
- Blood glucose measurement
- Cholesterol measurement
- Triglycerides
- Dehydration
- Hemoglobin
- Uric acid
- Lactate
- Body Fat Analyzer (BFA)
- Blood pressure - PTT

OUR RANGE OF VITAL SIGNS AND BIOMETRIC INDICATORS

ECG

TEMPERTURE

SPO2

STRESS TEST

HEART RATE

HOSPITAL & CLINICS – G MEDICAL PATCH (GMP)

SIMPLE AND CONTINUOUS, REAL-TIME VITAL SIGNS MONITORING SYSTEM

A reliable and convenient bio-sensors monitoring system, which can be used in both daily hospital care and post-discharge programs.

- Modular, simple solution that provides continuous, real-time monitoring.

- Data is transmitted to a centralised, secure backend system and is available on demand and by integration into EMRs in hospitals or call centres.

- Monitoring continues post patient discharge with the use of the G Medical Smartphone Jacket.

HOSPITAL & CLINICS – A COMPLETE FULL SOLUTION

MONITORING DEVICES

- Chest Patch - measures ECG, heart rate, respiration, body positioning.
- Add-on Blood Pressure.
- Add-on Ear Unit – measures Temperature and Spo2.

THE HUB - BACK END SYSTEM

- Receives and displays data from multiple patients.
- Single-and multi-patient screens.
- Use of algorithms to analyse incoming patient data.
- Alerts in case of a threshold breach.
- Generates reports.
- Available on smartphone and tablets.
- Remotely resets patient thresholds and parameters.

THE G MEDICAL GATEWAY

- Android-based smartwatch worn by the patient:
- Receives raw or filtered data from the sensors.
- Receives test results and displays them on the screen.
- Analyses raw data using algorithms and alerts in case of a threshold breach.
- Sends raw and final data to the backend (further analysis – save data to electronic medical record, generate reports).
- Technical alerts and messages (e.g., low sensor battery, disconnected sensor, etc.).

COVER FULL PATIENT''S HEALTHCARE LIFECYCLE

COMPREHENSIVE **SOLUTION FOR STREAMLINING PATIENT** CARE ACROSS

| PRE- **HOSPITALIZATION** | **HOSPITALIZATION** | POST-**DISCHARGE** |

PATIENTS HEALTHCARE LIFECYCLE

GMP

KEY ADVANTAGE

A modular, low cost alternative for healthcare providers

G MEDICAL
Mobility in Healthcare

CURRENT

Manual measurements taken by hospital staff

- Increased personnel
- Higher risk
- Low compliance
- Low accuracy

Bedside Monitoring System

- High cost
- Complex system
- Allows monitoring of only 20% of beds

G MEDICAL

Complementary of Vital Signs Monitoring

- low cost
- Easy to use
- Monitoring of up to 75% of beds
- Higher personnel efficiency

"monitoring more patients, made simpler, at lower costs"

IN HOSPITALS

- Improving patiente care
- Reducing malpractice cases
- Increasing cost efficiency
- Promoting early discharge

AT HOME

- Reducing Readmissions
- Reducing house calls
- Improving patient safety
- Continuous care
- Inhibiting disease deterioration

EMERGENCY SERVICES

- Efficient data transmission
- Real time patient information prior to arrival
- Preventing gaps in monitoring during transfer

NURSING HOMES

- Improving staff efficiency
- Improving patient safety and experience
- Improving nurse utilization

4

....

CALL CENTER
MEDICAL SERVICES

G MEDICAL CALL CENTER STRATEGY

TRUE INTEGRATION

- G Medical allows patients and professionals to track, monitor and share medical data and history

- Vital signs measures are automatically presented in a call center (IDTF) or hospital settings

- Looking at opportunities to acquire a medical call center in the USA to be integrated with G Medical platform -incorporating new technologies into the call center to boost revenues

- G Medical management know-how and experience in managing medical call center

CALL-CENTER FLOW – Prizma

1. Representative Dashboard including medical CRM access and incoming calls

2. IVR allocation of call to next available clinician

3. Caller identification process against CRM

4. Attending caller while reviewing CRM history and medical data Prizma portal

GMP Patients Monitoring Station

Single Patient View

Multiple Patients View

THANK YOU